Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 7INDUSTRY 4OTHER_GOV 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other neoplasm 1NET 1Gynecologic 1Endocrine 1

Conditions

Breast Neoplasms 63Neoplasms 40Colorectal Neoplasms 30Uterine Cervical Neoplasms 29Carcinoma, Hepatocellular 23Stomach Neoplasms 19Prostatic Neoplasms 19Carcinoma, Non-Small-Cell Lung 19Ovarian Neoplasms 16Lung Neoplasms 14Esophageal Neoplasms 13Multiple Myeloma 12Pancreatic Neoplasms 11Endometrial Neoplasms 10Urinary Bladder Neoplasms 9Motor Activity 9Colonic Neoplasms 9Recurrence 8Rectal Neoplasms 8Lymphoma, Follicular 8Melanoma 7Lymphoma 7Liver Neoplasms 7Carcinoma, Ovarian Epithelial 7Triple Negative Breast Neoplasms 6Sleep Initiation and Maintenance Disorders 6Sarcopenia 6Neuroendocrine Tumors 6Leukemia 6Hematologic Neoplasms 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × Hypersensitivity × 1 year × Clear all
NCT01837693 2025-06-26

NTCC2

Azienda USL Reggio Emilia - IRCCS

Phase NA Completed
41,127 enrolled
GynecologicOther neoplasm

Uterine Cervical Neoplasms, Hypersensitivity, Neoplasms, Precancerous Conditions

NCT01673906 2025-06-24

68-Ga-labeled Octreotide Analogues PET in Duodenal-pancreatic Neuroendocrine Tumours

Azienda USL Reggio Emilia - IRCCS

Phase 2 Completed
142 enrolled
EndocrineNET

Hypersensitivity, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡